CLDN18.2 CAR-T: questions for an advanced gastric cancer review

Clinical availability: Pending confirmation

Understand what needs to be assessed

Hearing about a new treatment can raise an immediate question: could it be relevant to me? The pathway described here concerns CLDN18.2-positive, HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma that has progressed after at least two prior lines of treatment. A specialist must assess the precise diagnosis, biomarker results, previous treatment and current health together. A positive biomarker alone does not establish suitability.

Separate the treatment information from your care plan

Before comparing options in China, ask which specific product and treatment criteria are being discussed, whether the hospital can assess your case and what the complete care pathway involves. Those are separate questions from whether a treatment has been reported in the news. The clinical team needs to explain potential benefits, side effects, limitations and monitoring in the context of your other choices.

How NEXA helps focus the discussion

We help organise the pathology and biomarker reports you already have, set out your treatment history and record the questions that matter to you and your family. We check with an appropriate team whether further assessment can be arranged and help clarify any missing information. The specialist team determines suitability and whether additional testing is needed.

Make the next conversation specific

Contact NEXA with your diagnosis, existing reports and previous treatments. We can help you clarify what review would cover, the service and cost questions to ask, and the arrangements needed during care and after returning home. You can start by asking whether the information you have is enough for a meaningful specialist discussion, before making a treatment or travel decision.